ArticleInternational urogynecology journal2026
Intravesical Instillation with Vivo-Morpholino Nerve Growth Factor Antisense Therapy Ameliorates Acute Interstitial Cystitis/Painful Bladder Syndrome-Related Urinary Frequency in a Rat Model.
Article in International urogynecology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introduction and hypothesisIncreased nerve growth factor (NGF) expression in the bladder is known to contribute to the hyperexcitability of C-fiber bladder afferent pathways in interstitial cystitis/painful bladder syndrome (IC/PBS). We hypothesized that intravesical administration of vivo-morpholino NGF antisense oligonucleotide (OND) would downregulate NGF expression and alleviate IC/PBS-associated urinary frequency.
methodsEighteen virgin female rats were randomly divided into three groups: (1) saline-injected control, (2) cyclophosphamide (CYP) plus intravesical instillation with normal saline, and (3) CYP plus intravesical instillation with vivo-morpholino NGF antisense OND (2 mg/kg). Female rats received an intravesical instillation of vivo-morpholino NGF antisense oligonucleotide once daily for three consecutive days, with a 30-min dwell time. Cystometric and histological evaluations were performed 24 h after the last instillation. Cystometry was used to evaluate voiding interval values under anesthesia, while NGF expression was measured.
resultsImmunohistochemistry demonstrated a ~ 26% increase in bladder NGF expression in CYP-induced IC/PBS rats compared with controls, particularly in the urothelium and suburothelium, whereas intravesical NGF antisense therapy reduced NGF levels by ~ 28%, approaching control values. Cystometric analysis revealed that CYP treatment reduced voiding intervals by ~ 61% at 24 h and ~ 40% at 48 h compared to controls, consistent with bladder overactivity. NGF antisense therapy markedly prolonged voiding intervals, increasing them by ~ 113% at 24 h and ~ 80% at 48 h compared with CYP, indicating progressive functional improvement. Baseline and maximal bladder pressures were not significantly different among groups.
conclusionsIntravesical administration of vivo-morpholino NGF antisense OND significantly prolonged voiding intervals and attenuated bladder NGF expression in CYP-induced acute IC/PBS female rats. These results highlight the potential of NGF antisense OND as a novel intravesical therapy for IC/PBS.
Indexed as
Identifiers
41137924What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.